New Insights on Omega-3 Fish Oil's Impact on Insulin Resistance in Non-Obese Diabetes

The role of omega-3 fish oil in combating insulin resistance has garnered attention, particularly in cases of type 2 diabetes that don’t align with the common narrative of obesity. A recent Brazilian study published in Nutrients revealed that omega-3 fatty acids can enhance glucose tolerance and mitigate insulin resistance in non-obese rats exhibiting diabetes-like conditions.

This research, supported by FAPESP, utilized Goto-Kakizaki (GK) rats, a proven animal model for studying non-obese type 2 diabetes. Unlike the typical portrayal of type 2 diabetes, which emphasizes obesity as a primary risk factor, this study demonstrated that approximately 10-20% of those affected are not obese but still exhibit the disease's metabolic complications.

In the eight-week experiment, the rats received fish oil at a dosage of 2 grams per kilogram of body weight, translating to 540 mg/g of eicosapentaenoic acid (EPA) and 100 mg/g of docosahexaenoic acid (DHA) three times a week. Post-treatment evaluations indicated a notable reduction in insulin resistance, improvements in blood sugar levels, and decreased inflammatory markers. Additionally, several lipid profiles, including total cholesterol, LDL cholesterol, and triglycerides, were favorably affected.

While the findings stem from preclinical studies and require caution before generalizing to human populations, they underscore the inflammatory response's significance in non-obese diabetes and suggest a potential pathway for omega-3 fatty acids in addressing this issue.

Rui Curi, the study’s coordinator and a prominent figure at the Butantan Institute and Cruzeiro do Sul University (UNICSUL), highlighted the modulation of inflammatory responses as a key mechanism. The experiments revealed that administering fish oil could shift the behavior of lymphocytes—specific white blood cells that play a pivotal role in immune responses—from a pro-inflammatory to an anti-inflammatory profile. This shift mirrors responses observed in obese individuals experiencing insulin resistance due to omega-3 supplementation.

Identifying the dynamics of immune cells is vital since changes in lymphocyte behavior can have cascading effects throughout the immune system and influence inflammation. Curi elaborated on previous studies where non-obese rats showed inflammatory markers akin to changes seen in obese diabetic models, raising questions about distinct biological pathways contributing to insulin resistance.

Renata Gorjão, co-director of UNICSUL's Graduate Studies Program, emphasized that the study aimed to clarify whether omega-3-rich fish oil supplementation could reverse the immune profile alterations that predispose non-obese subjects to insulin resistance. The research confirmed that inflammation remains a crucial factor in diabetes, independent of obesity.

Aside from inflammation, genetic predispositions are also being investigated as contributing factors for non-obese diabetes. In a concurrent study published in Cells, Curi and his team examined whether delays in intestinal transit could play a role in insulin resistance among this demographic.

In discussing obesity's influence on diabetes, Curi noted that people with chronic low-level inflammation often exhibit disruptions in insulin signaling pathways. While adipose tissue in obesity facilitates inflammatory cytokine production, non-obese models still suffer from systemic inflammation, albeit lacking the excessive adipose tissue characteristic of obesity.

The Nutrients publication further explored how fish oil supplementation appears to transition immune responses towards a more protective state. Lobato, a researcher involved in the study, commented on the anti-inflammatory effects of omega-3 supplementation, particularly highlighting its ability to decrease specific pro-inflammatory lymphocyte subtypes while promoting regulatory T-cells (Tregs), which help inhibit inflammation-driven immune responses.

This immune modulation reinforces the connection between inflammation and insulin resistance, suggesting that managing inflammatory signals could optimize insulin response mechanisms. The study aligns with a growing perspective on type 2 diabetes as an interplay of metabolic and immune system dysfunctions.

Subsequent human research supports these findings, with ongoing studies into how omega-3 fatty acids can influence diabetes risk and metabolic health. For instance, a double-blind randomized controlled trial scheduled for 2025 in Food and Function intends to observe potential improvements in insulin sensitivity and overall metabolic markers among older adults given fish oil.

Another analysis featured in Nutrition and Diabetes in 2024 suggested a dose-dependent relationship between omega-3 levels and long-term blood sugar control, advocating for further exploration into individualized dietary recommendations involving omega-3s for diabetes management. Nonetheless, this area remains complex and somewhat contentious within the medical community.

Despite the promising nature of these studies, researchers including Curi assert the need for caution in interpreting results, as animal research cannot offer definitive evidence of efficacy in humans. Clinical trials are essential to determine the optimal dosing and types of omega-3 fatty acids beneficial for individuals with non-obese type 2 diabetes.

Ultimately, this investigation presents a compelling insight into the multifaceted nature of type 2 diabetes, revealing that factors beyond body weight significantly contribute to insulin resistance. Understanding how inflammation interacts with insulin sensitivity may hold the key to revealing new pathways for intervention.

Materials provided by São Paulo Research Foundation (FAPESP). Note: Content may be edited for style and length.